ERBB2 and breast carcinoma: Tumors classified as high-risk cancer with poor prognosis include triple-negative and HER2 positive breast cancer, patients with lymph node involvement4 and patients classified through multigene mRNA signatures such as Endopredict® (Myriad Genetics Inc., Salt Lake City, Utah, USA), OncotypeDX® (Genomic Health, Redwood City, CA, USA) or Mammaprint® (Agendia Inc., Irvine, CA, USA) to be at high risk to develop metastasis5,6.